A news piece in this week's Science reports that ECell International (ESI), a Singapore-based company, is stopping research work on human embryonic stem cells due to increasing lack of investor interest. The time lag from lab to clinic is too long, investors say, but several companies, including Geron and ACT, are not giving up, claiming they have products in the pipeline.